OP0049 COMPARISON OF BASELINE DISEASE ACTIVITY AND PATIENT (PT)-REPORTED OUTCOMES (PROS) BETWEEN PTS WITH PSORIATIC ARTHRITIS AND AXIAL INVOLVEMENT (AXIAL PSA) AND AXIAL SPONDYLOARTHRITIS (AXIAL SPA) FROM THE CORRONA PSA/SPA REGISTRY

Background: Although pts with axial PsA and SpA share some common clinical characteristics, there are also potential differences that may influence disease assessment treatment response. Identifying between the two pt populations is important for of characteristics severity as well informing decisions. There has been little comparative characterization these conditions in a US population. Objectives: To compare SpA. Methods: Pts ≥18 years age diagnosed or at enrollment prospective, multicenter, observational Corrona PsA/SpA Registry March 2013 August 2020 were included. Enrollment visit demographics, history, activity measures, PROs compared groups. Continuous measures reported using means standard deviations; groups two-sample t tests Wilcoxon rank sum tests. Categorical frequencies percentages; chi-square Fisher exact Results: A total 1044 (470 574 SpA) identified (Table). older higher percentage being female vs Time since symptom onset diagnosis shorter (12.0 15.6 [ P <0.001] 6.8 8.3 =0.01]). less likely than to have current historical uveitis (4% 14% <0.001]) inflammatory bowel (5% 10% =0.005]). Prior biologic synthetic disease-modifying antirheumatic drug (bDMARD) conventional DMARD use was more prevalent (64% 52% <0.001]/59% 32% <0.001]), while mean dactylitis (measured by Dactylitis Count) enthesitis Spondyloarthritis Research Consortium Canada [SPARCC] Enthesitis Index) counts (0.4 0.1 <0.001]/1.7 1.2 <0.001]). Mean pt-reported pain spinal lower (49.4 53.9 =0.015]/40.8 49.7 (Figure). The proportion morning stiffness along fatigue work impairment scores similar Table. Baseline demographics Axial N=470 N=574 value Age (years), ± SD 51.6 13.2 47.7 14.0 <0.001 Female, n (%) 265 (57) 248 (44) White, 428 (94) 507 (91) 0.089 Years onset, 12.0 11.6 12.1 diagnosis, 9.0 10.5 0.010 HLA-B27 positive status, n/n 52/189 (28) 214/295 (73) Abnormal CRP, 88 (19) 140 (24) 0.033 Uveitis, 20 (4) 80 (14) IBD, 25 (5) 59 (10) 0.005 count, 0.4 1.5 0.7 SPARCC 1.7 2.9 2.4 Morning stiffness, 439 (95) 537 (96) 0.923 BASDAI (0–10), 4.8 2.5 4.9 0.463 Q2 (0–10): pain, 5.0 5.7 Q3 peripheral pain/swelling, 4.5 4.0 3.1 Modified 5.4 0.013 bDMARDs, 300 (64) 299 (52) csDMARDs, 275 (59) 181 (32) prednisone use, 54 (12) 73 (13) 0.611 NSAID 52 (11) 46 (8) 0.115 Conclusion: Findings from this descriptive real-world analysis suggest be meaningful but future studies needed better understand differences. Acknowledgements: Medical writing services provided Alan Saltzman Fishawack Facilitate Ltd, part Health, funded AbbVie. This study sponsored Corrona, LLC. supported through contracted subscriptions last 2 AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Crescendo, Eli Lilly Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Pfizer, Regeneron, Roche, Sun, UCB, Valeant. design, conduct, financial support AbbVie participated interpretation data, review, approval abstract. No honoraria payments made authorship. Disclosure Interests: Philip J Mease Speakers bureau: Lilly, Consultant of: BMS, Galapagos, GlaxoSmithKline, Grant/research from: Maya Marchese Employee Robert McLean Taylor Blachley Laura Anatale-Tardiff Christopher Saffore Shareholder Elizabeth Lesser Alexis Ogdie National Institutes Health/National Institute Arthritis Musculoskeletal Skin Diseases, Rheumatology Foundation, Psoriasis Novartis